Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
OXBT [NASD]
Oxygen Biotherapeutics, Inc.
Index- P/E- EPS (ttm)-0.52 Insider Own0.05% Shs Outstand23.39M Perf Week-3.37%
Market Cap107.36M Forward P/E- EPS next Y- Insider Trans- Shs Float2.41M Perf Month8.77%
Income-15.06M PEG- EPS next Q- Inst Own6.47% Short Float9.43% Perf Quarter-56.53%
Sales0.04M P/S2684.00 EPS this Y-35.41% Inst Trans8.61% Short Ratio15.06 Perf Half Y-74.21%
Book/sh-0.05 P/B- EPS next Y- ROA-372.23% Target Price3.00 Perf Year-86.01%
Cash/sh0.06 P/C71.10 EPS next 5Y- ROE- 52W Range3.51 - 45.00 Perf YTD-64.36%
Dividend- P/FCF- EPS past 5Y0.00% ROI-647.76% 52W High-89.80% Beta0.31
Dividend %- Quick Ratio1.49 Sales past 5Y- Gross Margin46.56% 52W Low30.95% ATR0.51
Employees15 Current Ratio1.57 Sales Q/Q-46.86% Oper. Margin-15374.98% RSI (14)48.35 Volatility10.38% 12.03%
OptionableNo Debt/Eq- EPS Q/Q60.55% Profit Margin-37974.78% Rel Volume0.42 Prev Close4.49
ShortableYes LT Debt/Eq- EarningsMar 18 Payout- Avg Volume15.09K Price4.59
Recom3.00 SMA20-0.95% SMA50-3.69% SMA200-61.69% Volume6,300 Change2.23%
21-May-13 10:30AM  Oxygen Biotherapeutics Names Col. Charles L. Pamplin III, M.D., Chief Medical Officer Business Wire
16-May-13 10:21AM  Oxygen Biotherapeutics Receives Favorable NASDAQ Listing Decision Business Wire -6.96%
03:28AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
15-May-13 09:24AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Oth EDGAR Online
10-May-13 01:09PM  InPlay: Oxygen Biotherapeutics announces 20:1 reverse stock split effective after market close on May 10th Briefing.com
01:09PM  Oxygen Biotherapeutics Announces 20:1 Reverse Stock Split Effective After Market Close on May 10th Business Wire
01-May-13 09:15AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online -6.80%
30-Apr-13 08:01AM  Oxygen Biotherapeutics to begin enrollment in second cohort of STOP-TBI trial at theflyonthewall.com
08:00AM  Oxygen Biotherapeutics Announces It is Set to Begin Enrolling Patients in the Second Cohort of Its STOP-TBI Clinical Trial in Israel Business Wire
05-Apr-13 10:09AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule o EDGAR Online
22-Mar-13 01:04PM  OXYGEN BIOTHERAPEUTICS, INC. Financials EDGAR Online Financials
21-Mar-13 09:16AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule o EDGAR Online
19-Mar-13 11:00AM  Oxygen Biotherapeutics, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
04:16AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
12:34AM  Oxygen Biotherapeutics, Inc. Earnings Call scheduled for 11:00 am ET today CCBN
18-Mar-13 05:31PM  Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2013 Business Wire
09:30AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q3 2013 Oxygen Biotherapeutics, Inc. Earnings Release - Time Not Supplied CCBN
14-Mar-13 04:25PM  Thursday movers: Apple up 1% ahead of Samsung show at MarketWatch +6.87%
01:40PM  Thursday movers: EBay recovers from steep selloff at MarketWatch
12:23PM  Thursday movers: Apple up ahead of Samsung event at MarketWatch
10:55AM  Thursday movers: Ackman steps up Herbalife seige at MarketWatch
08:07AM  Thursdays movers: Mens Wearhouse, E*Trade at MarketWatch
13-Mar-13 04:45PM  Oxygen Biotherapeutics Announces Third Quarter FY2013 Financial Results Conference Call and Webcast Business Wire -9.34%
08-Mar-13 02:14PM  5 Stocks Ready to Break Out at TheStreet +19.12%
27-Feb-13 05:27PM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K/A, Financial Statements and Exhibits EDGAR Online
25-Feb-13 06:02AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equ EDGAR Online
22-Feb-13 09:00AM  Oxygen Biotherapeutics raise $2.1M in sale of preferred stock to investor theflyonthewall.com -33.00%
08:59AM  InPlay: Oxygen Biotherapeutics Enters into Definitive Agreements for Financing for up to $2.1 Million in Gross Proceeds Briefing.com
08:58AM  Oxygen Biotherapeutics Enters into Definitive Agreements for Financing for up to $2.1 Million in Gross Proceeds Business Wire
20-Feb-13 11:05AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events EDGAR Online
11:04AM  InPlay: Oxygen Biotherapeutics announces tentative settlement of litigation; tentative agreement provides that the co will settle the matter for $600,000 in cash Briefing.com
11:03AM  Oxygen Biotherapeutics Announces Tentative Settlement of Litigation Business Wire
11-Feb-13 05:19PM  InPlay: Oxygen Biotherapeutics enters License and Supply agreement for Dermacyte products with the cosmetics division of Valor SA Briefing.com -10.34%
05:15PM  Oxygen Biotherapeutics Enters License and Supply Agreement for Dermacyte® Products with the Cosmetics Division of Valor SA Business Wire
05:01PM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events EDGAR Online
06-Feb-13 08:30AM  Oxygen Biotherapeutics and the U.S. Army Institute of Surgical Research Sign a Cooperative Research and Development Agreement to Study the Effects of Oxycyte® on Ex Vivo Platelet Function Business Wire -8.57%
30-Jan-13 08:28PM  Oxygen Biotherapeutics Announces It Will Present at the 15th Annual BIO CEO & Investor Conference on February 11 Business Wire
08:30AM  Oxygen Biotherapeutics Announces It Will Present at the 15th Annual BIO CEO & Investor Conference on February 11 Business Wire
08-Jan-13 08:44PM  Oxygen Biotherapeutics Announces It Will Present at OneMedForum Conference on Wednesday January 9th Business Wire
20-Dec-12 01:04PM  OXYGEN BIOTHERAPEUTICS, INC. Financials EDGAR Online Financials
17-Dec-12 08:21AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online -7.92%
07:15AM  Oxygen Biotherapeutics Reports Second Quarter FY2013 Financial Results Business Wire
14-Dec-12 04:39PM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
09:24AM  New Stock Coverage: Microsoft Still Has Major Issues at Minyanville
07:07AM  Q2 2013 Oxygen Biotherapeutics, Inc. Earnings Release - Time Not Supplied CCBN
05:30AM  Big earnings Friday: Ricks Cabaret, Ocean Power at MarketWatch
06-Dec-12 02:43PM  Oxygen Biotherapeutics Announces Second Quarter FY2013 Financial Results Conference Call and Webcast Business Wire
20-Nov-12 10:31AM  PPD to test Oxygen Biotherapeutics drug at bizjournals.com
08:30AM  Oxygen Biotherapeutics Engages PPD to Execute Remainder of Phase IIb Clinical Trial to Evaluate the Safety and Tolerability of Oxycyte® in Severe Traumatic Brain Injury Business Wire
26-Oct-12 06:58AM  Oxygen trying to get proposed drug back on track at bizjournals.com
25-Oct-12 05:02PM  Oxygen trying to get proposed drug back on track at bizjournals.com
08:06AM  InPlay: Oxygen Biotherapeutics' update on U.S. Army-funded preclinical studies designed to support the safety profile of Oxycyte PFC emulsion currently in clinical trials overseas for traumatic brain injury Briefing.com
08:00AM  Oxygen Biotherapeutics Update on U.S. Army-Funded Preclinical Studies Designed to Support the Safety Profile of Oxycyte PFC Emulsion Currently in Clinical Trials Overseas for Traumatic Brain Injury Business Wire
08-Oct-12 01:51PM  Delisting danger deja vu for Oxygen Biotherapeutics at bizjournals.com -8.68%
05-Oct-12 04:31PM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule o EDGAR Online +11.36%
03-Oct-12 08:05AM  InPlay: Oxygen Biotherapeutics signs cooperative research and development agreement with U.S. navy to investigate the use of Oxycyte PFC emulsion as an adjunctive treatment of complex infected wounds and related injuries Briefing.com +16.36%
08:02AM  Oxygen Biotherapeutics signs R&D agreement with U.S. Navy at theflyonthewall.com
08:00AM  Oxygen Biotherapeutics Signs Cooperative Research and Development Agreement with U.S. Navy to Investigate the Use of Oxycyte PFC Emulsion as an Adjunctive Treatment of Complex Infected Wounds and Related Injuries Business Wire
25-Sep-12 01:04PM  OXYGEN BIOTHERAPEUTICS, INC. Financials EDGAR Online Financials
21-Sep-12 10:00AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule o EDGAR Online
20-Sep-12 06:02AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
19-Sep-12 05:30PM  Oxygen Biotherapeutics Reports First Quarter FY2013 Financial Results Business Wire -6.84%
04:58PM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q1 2013 Oxygen Biotherapeutics, Inc. Earnings Release - Time Not Supplied CCBN
17-Sep-12 10:33AM  Oxygen Biotherapeutics Announces First Quarter FY2013 Financial Results Conference Call and Webcast Business Wire
07-Sep-12 05:04PM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders EDGAR Online
29-Aug-12 07:17AM  InPlay: Oxygen Biotherapeutics relocating R&D function to North Carolina from California; successfully subleased its Costa Mesa facility at terms that made the transition cost effective Briefing.com
28-Aug-12 05:02PM  Oxygen Biotherapeutics relocating R&D function to North Carolina at theflyonthewall.com
05:00PM  Oxygen Biotherapeutics Relocating R&D Function to North Carolina from California Business Wire
04:35PM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits EDGAR Online
21-Aug-12 07:02AM  InPlay: Oxygen Biotherapeutics: University of Glasgow study demonstrates the ability of Oxycyte to supply oxygen to critical penumbral tissue in acute ischemic stroke Briefing.com -7.84%
07:00AM  University of Glasgow Study Demonstrates the Ability of Oxycyte® to Supply Oxygen to Critical Penumbral Tissue in Acute Ischemic Stroke Business Wire
02-Aug-12 08:02AM  InPlay: Oxygen Biotherapeutics and U.S. Navy expand collaboration with Cooperative Research & Development Agreement Briefing.com
08:00AM  Oxygen Biotherapeutics and U.S. Navy Expand Collaboration with Cooperative Research & Development Agreement to Study Oxycyte® for Treatment of Hemorrhagic Shock Business Wire
28-Jul-12 01:04PM  OXYGEN BIOTHERAPEUTICS, INC. Financials EDGAR Online Financials
25-Jul-12 11:00AM  Oxygen Biotherapeutics Inc Earnings Call scheduled for 11:00 am ET today CCBN
10:46AM  Oxygen Biotherapeutics Inc Earnings Call scheduled for 11:00 am ET today CCBN
06:03AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
06:03AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 10-K, Annual Report EDGAR Online
24-Jul-12 06:33PM  Oxygen Biotherapeutics Reports Financial Results for Fiscal Year 2012 Business Wire
07:07AM  Q4 2012 Oxygen Biotherapeutics, Inc. Earnings Release - Time Not Supplied CCBN
28-Jun-12 01:30PM  Oxygen Biotherapeutics Sets Year-End Financial Results Conference Call and Webcast for July 25th and General Annual Meeting for August 31st GlobeNewswire
15-Jun-12 08:08AM  InPlay: Oxygen Biotherapeutics announces expected closing on second installment of Dec 2011 financing and amends agreement to allow for a third tranche later this year pending shareholder approval Briefing.com -10.87%
08:05AM  Oxygen Biotherapeutics Announces Expected Closing on Second Installment of December 2011 Financing and Amends Agreement to Allow for a Third Tranche Later This Year Pending Shareholder Approval GlobeNewswire
08:02AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial EDGAR Online
31-May-12 09:39AM  InPlay: Oxygen Biotherapeutics study reveals Dermacyte concentrate's potential to relieve histamine-induced pruritus in healthy patients Briefing.com +5.79%
09:38AM  Oxygen Biotherapeutics Study Reveals Dermacyte(R) Concentrate's Potential to Relieve Histamine-Induced Pruritus in Healthy Patients GlobeNewswire
03-May-12 10:49AM  InPlay: Oxygen Biotherapeutics secures long-term clinical supply of Oxycyte Briefing.com
10:47AM  Oxygen Biotherapeutics Secures Long-Term Clinical Supply of Oxycyte(R) GlobeNewswire
12-Apr-12 04:56PM  Health Care Sector Wrap at Fox Business -7.73%
22-Mar-12 01:04PM  OXYGEN BIOTHERAPEUTICS, INC. Financials EDGAR Online Financials
16-Mar-12 11:00AM  Oxygen Biotherapeutics Inc Earnings Call scheduled for 11:00 am ET today CCBN
06:05AM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements EDGAR Online
15-Mar-12 10:21PM  Oxygen Biotherapeutics Reports Financial Results for the Third Quarter FY2012 GlobeNewswire
05:17PM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report EDGAR Online
07:07AM  Q3 2012 Oxygen Biotherapeutics, Inc. Earnings Release - Time Not Supplied CCBN
01-Mar-12 04:46PM  InPlay: Oxygen Biotherapeutics announces plan to regionalize its sales & marketing efforts for its dermacyte oxygenating skin care product line Briefing.com
04:44PM  Oxygen Biotherapeutics Announces Plan to Regionalize Its Sales & Marketing Efforts for Its Dermacyte(R) Oxygenating Skin Care Product Line GlobeNewswire
04:18PM  OXYGEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement EDGAR Online
Oxygen Biotherapeutics, Inc., a development stage company, engages in developing biotechnology products that deliver oxygen to target tissues in the body primarily in the United States. It develops Oxycyte, a systemic perfluorocarbon (PFC) based oil in water emulsion oxygen carrier for use in situations of acute ischemia; and is in Phase II-b clinical trial for the treatment of traumatic brain injury. The company also offers Dermacyte line of topical cosmetic products that promote the appearance of skin health and other cosmetic benefits; and Wundecyte, a wound-healing gel. Oxygen Biotherapeutics, Inc. sells its Dermacyte products through online retailers, physician, and medical spa facilities, as well as through distribution agreements with unrelated companies. The company was formerly known as Synthetic Blood International, Inc. and changed its name to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics, Inc. was founded in 1967 and is headquartered in Morrisville, North Carolina.